<DOC>
	<DOCNO>NCT01839214</DOCNO>
	<brief_summary>This study examine safety efficacy subject mild moderate ulcerative colitis , measure Modified Mayo Score , Modified Baron Score , IBDQ , calprotectin assessment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety VB-201 Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female , ≥18 year age , diagnosis active UC least 6 month prior screen A rectal/colonic biopsy obtain previously consistent diagnosis UC Endoscopy ( flexible sigmoidoscopy unless surveillance colonoscopy clinically indicate ) confirm diagnosis UC within 2 week prior randomization Endoscopy ( flexible sigmoidoscopy unless surveillance colonoscopy clinically indicate ) confirm diagnosis UC within 2 week prior randomization Active UC despite previous treatment least one 5ASA compound dose ≥2000 mg/day least 4 week document intolerance therapy Diagnosis indeterminate colitis , Crohn 's disease , clinical finding suggestive Crohn 's disease ( fistula granuloma biopsy ) microscopic colitis ( collagenous colitis lymphocytic colitis ) Subject whose symptom likely cause factor inflammatory UC , include infection irritable bowel syndrome ( IBS ) History dysplasia colonic biopsy Subject ≥ 8 year history pancolitis ≥ 15 year history leave sided colitis unless colonoscopy surveillance biopsy screen colon cancer perform within past year Subject ≥ 50 year age colonoscopy screen colorectal polyp colon cancer within past 5 year Subject prior surgical resection part colon exclude appendix Previous treatment biologic product include investigational biologic product within 1 year prior baseline visit The subject take Systemic corticosteroid , Azathioprine/6mercaptopurine/methotrexate , immunosuppressant , Oral 5ASA compound unless stable dose sufficient duration prior Baseline . If recently discontinue subject must washout period sufficient duration prior Baseline Rectally administer corticosteroid 5ASA , antibiotic treatment UC probiotic within 14 day Baseline Visit throughout study The subject stool culture positive pathogenic ovum parasite , enteric pathogen Clostridium difficile toxin Screening Visit Presence , history cancer , exception skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>